AGC Biologics Revenue and Competitors

AGC Biologics is a leading global Contract Development and Manufacturing Organization (CDMO), with a relentless commitment to deliver the highest standard of service to our clients and partners. AGC Biologics is the product of the convergence and integration of Asahi Glass Company (AGC) Life Sciences, CMC Biologics, and BIOMEVA GmbH. Our extensive network spans three continents, with cGMP-compliant facilities in Seattle, WA; Berkeley, CA; Copenhagen, Denmark; Heidelberg, Germany; Yokohama, Japan; and Chiba, Japan. AGC Biologics offers deep industry expertise and uniquely customized services for the scale-up and cGMP manufacture of protein-based therapeutics, from pre-clinical to commercial production, both mammalian and microbial. Our integrated service offerings include cell line development, bioprocess development, formulation, analytical testing, antibody drug development and conjugation, cell banking and storage, and protein expression including our proprietary CHEF1® Expression System for mammalian production. Our company DNA drives us to provide innovative solutions for clients to reach their goals and accelerate their projects, as well as facilitate approval and manage spending during the product lifecycle. AGC Biologics forges exceptionally strong partnerships with our clients, and we never lose sight of our commitment to deliver reliable and compliant drug substance supply, on time. Visit www.agcbio.com to learn why AGC Biologics is a World Leader in process development and contract manufacturing.